Women develop rheumatic and musculoskeletal diseases (RMDs) at significantly higher rates than men — yet they consistently face longer diagnostic delays, longer wait times, and less access to advanced therapies. A new viewpoint published in Annals of the Rheumatic Diseases argues that much of this disparity stems from gender bias that is often invisible, even to the clinicians perpetuating it. Historically, diagnostic criteria were built around how diseases present in men, and women's pain has long been normalized or dismissed as stress or anxiety.

The problem doesn't stop at the clinic door. Caregiving responsibilities — shouldered by women 66% of the time — can delay appointment-seeking, and psychosocial stress has been linked to elevated autoimmune disease risk in postmenopausal women. Reproductive health concerns are also frequently overlooked in rheumatology visits, though a recent study showed that simple EHR workflow changes and medical assistant involvement can dramatically improve documentation of contraception and pregnancy intent.

By the Numbers:

• Osteoarthritis affects 18% of women vs. 9.6% of men over age 60
• RA incidence is ~3× higher in women
• SLE incidence: 8.82 vs. 1.53 per 100,000 person-years (women vs. men)
• Women with axial spondyloarthritis wait an average of 8 years for diagnosis vs. 6 years for men
• Post-COVID, women still waited 7.5 days longer for rheumatology appointments than men

Why it matters: Gender bias in rheumatology isn't just a fairness issue — it leads to real delays in diagnosis and treatment that worsen long-term outcomes. Experts say rheumatologists can start closing the gap today by auditing their own data, training staff on bias, and asking patients about caregiving burdens and reproductive health.